Drug Type Bispecific antibody |
Synonyms ATOR 1144 |
Target |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), GITR inhibitors(Glucocorticoid-induced tumor necrosis factor receptor-related protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | SE | 17 Oct 2018 | |
Solid tumor | Preclinical | SE | 15 Oct 2018 |